Case 3
This 72-year-old man presented with an L-1 burst fracture after a fall (Day 1). He required urinary catheterization and subsequently developed a UTI (Day 5) that was treated with a 3-day course of oral levofloxacin (500 mg/day). On Day 9, both the PT (14.8 seconds) and INR (1.3) became elevated compared with admission levels (PT 11.9 seconds, INR 1), although they became normalized (PT 12.1 seconds, INR 1) following a 4-day course of subcutaneously administered vitamin K (10 mg/day). Subsequent surgery on Day 14 was unremarkable, and results of his clotting studies remained normal.
Discussion
Fluoroquinolones are broad-spectrum antibiotics routinely prescribed by many neurosurgical services for the treatment of UTIs. Although they are not considered to be firstline therapy for such infections, their ease of administration, favorable pharmacokinetic properties, negligible cross-resistance with other antibiotics, and excellent tolerability make them widely appealing. 1, 16 Despite these advantages, there is an association between the fluoroquinolone ciprofloxacin and bleeding diathesis. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] 15 Van Beek, et al., 15 drew attention to a possible association between ciprofloxacin and the development of a short-lived inhibitor against factor VIII. In their study a patient with severe hemophilia and neurogenic bladder was given norfloxacin and ciprofloxacin for hemorrhagic cystitis and subsequently developed severe postoperative bleeding following surgical drainage of a muscle abscess.
Furthermore, fluoroquinolones have been shown to exaggerate bleeding in patients taking warfarin, 15 and ciprofloxacin has been shown to interfere with the hepatic metabolism of warfarin. 5, 6, 12 In fact, hemorrhagic events from hypoprothrombinemia attributed to ciprofloxacin-warfarin interactions have been reported in sufficient numbers to warrant concern in prescribing this drug combination. [5] [6] [7] [8] [9] [10] 12 Castamen and colleagues 3,4 demonstrated a long-lasting proteolysis of plasma von Willebrand factor in two patients who had received ciprofloxacin and developed a transitory von Willebrand syndrome. Our data indicate a similar problem with the structurally related antibiotic levofloxacin. 1, 2, 16 In the patient in Case 1, factor VIII/von Willebrand factor measurements were reduced, bleeding times were prolonged, and ristocetin aggregation was decreased, thus confirming the diagnosis. Note that acquired factor VIII and von Willebrand factor inhibitors were not present to suggest an immune-related origin, and none of our patients were taking warfarin or any other drug known to react adversely with levofloxacin and cause this disturbance. [5] [6] [7] [8] [9] [10] The precise factor(s) responsible for the observed abnormalities remain unknown, but based on the striking similarities between one recent report on ciprofloxacin 3,4 and our experience, this potentially important and unexplored association needs further investigation.
Von Willebrand disease is an abnormality of hemostasis in which there is a reduction in the concentration or structure of a protein, the von Willebrand factor, which ordinarily binds to platelets and factor VIII and mediates adhesion to subendothelial collagen during platelet plug formation. 3, 4 This results in a characteristic combination of laboratory abnormalities. First, the bleeding time is prolonged, as expected in any platelet disorder. Second, the platelets in these patients do not aggregate in vitro, as normal platelets do, when exposed to the obsolete antibiotic ristocetin. Last, factor VIII activity is reduced as a consequence of the relationship between this clotting factor and von Willebrand factor.
More commonly, antibiotics have been reported to cause coagulopathies by altering vitamin K metabolism. 13, 14 The two postulated mechanisms implicate either direct inhibition of biosynthesis of vitamin K-dependent clotting factors by the N-methylthiotetrazole moiety found in certain antimicrobial agents, or eradication of vitamin K-producing intestinal microflora in patients with reduced vitamin K intake. 13 Our patients were elderly and poorly nourished (albumin levels Ͻ 2.7 g/100 ml), and developed prolonged PTs and INRs shortly after levofloxacin administration, which were reversed with vitamin K. The clear rise in PT and INR levels after levofloxacin administration, the lack of an N-methylthiotetrazole side chain on fluoroquinolones, and the rapid response to vitamin K indicate that the population of vitamin K-dependent bowel flora were altered. Contrary to the popular belief that any class of broad-spectrum antibiotic can do the same, 14 only a few have been implicated, 13 and the propensity of levofloxacin to do so is worthy of notice.
To ascertain the frequency of coagulopathies in patients with spine disease treated with levofloxacin, we reviewed the charts of 28 levofloxacin-treated patients in our spine service between October 2001 and October 2002. Six patients were found to have prolonged PTs and increased INRs after levofloxacin administration, but precise hematological data in three of these patients were lacking because coagulation profiles were not routinely obtained before levofloxacin administration in the past. These three patients received levofloxacin preoperatively for UTIs and were found to have prolonged PTs and increased INRs on surveillance clotting studies postoperatively. Although it is conceivable that coagulopathy in these patients was associated with levofloxacin, the stress of surgery could have also contributed to prolonged clotting profiles. 13 Considering this, we estimate the incidence of levofloxacin-induced coagulopathies in our study to be between 11and 21%, a rate similar to those in other reports on antimicrobial-induced coagulopathies.
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Conclusions
There seems to be an association between levofloxacin and coagulation abnormalities in neurosurgical patients treated for UTIs. At this point we are not discouraging the use of this common antibiotic, but neurosurgical services should be aware of this potential problem and closely monitor PT and INR levels if this drug is used, especially in elderly, malnourished, or other high-risk patients.
